Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 153

1.

Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study.

Langenfeld MR, Forst T, Hohberg C, Kann P, Lübben G, Konrad T, Füllert SD, Sachara C, Pfützner A.

Circulation. 2005 May 17;111(19):2525-31. Epub 2005 May 9.

2.

Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483.

PMID:
16861090
3.

Pharmacological PPARgamma stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes.

Forst T, Hohberg C, Fuellert SD, Lübben G, Konrad T, Löbig M, Weber MM, Sachara C, Gottschall V, Pfützner A.

Horm Metab Res. 2005 Aug;37(8):521-7.

PMID:
16138267
4.

Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus.

Davidson M, Meyer PM, Haffner S, Feinstein S, D'Agostino R Sr, Kondos GT, Perez A, Chen Z, Mazzone T.

Circulation. 2008 Apr 22;117(16):2123-30. doi: 10.1161/CIRCULATIONAHA.107.746610. Epub 2008 Apr 14.

5.

Nateglinide reduces carotid intima-media thickening in type 2 diabetic patients under good glycemic control.

Mita T, Watada H, Shimizu T, Tamura Y, Sato F, Watanabe T, Choi JB, Hirose T, Tanaka Y, Kawamori R.

Arterioscler Thromb Vasc Biol. 2007 Nov;27(11):2456-62. Epub 2007 Sep 13.

6.
8.

Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.

Derosa G, Cicero AF, Gaddi AV, Ciccarelli L, Piccinni MN, Salvadeo S, Pricolo F, Fogari E, Ghelfi M, Ferrari I, Fogari R.

Clin Ther. 2005 Sep;27(9):1383-91.

PMID:
16291411
10.
11.

A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes.

Stocker DJ, Taylor AJ, Langley RW, Jezior MR, Vigersky RA.

Am Heart J. 2007 Mar;153(3):445.e1-6.

PMID:
17307426
12.

Two-year statin therapy does not alter the progression of intima-media thickness in patients with type 2 diabetes without manifest cardiovascular disease.

Beishuizen ED, van de Ree MA, Jukema JW, Tamsma JT, van der Vijver JC, Meinders AE, Putter H, Huisman MV.

Diabetes Care. 2004 Dec;27(12):2887-92.

PMID:
15562202
13.

Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

J Clin Pharm Ther. 2006 Aug;31(4):375-83.

PMID:
16882108
14.

Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome.

Derosa G, Gaddi AV, Piccinni MN, Ciccarelli L, Salvadeo S, Peros E, Ghelfi M, Ferrari I, Cicero AF.

Pharmacotherapy. 2005 May;25(5):637-45.

PMID:
15899724
15.

Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride.

Pfützner A, Schöndorf T, Seidel D, Winkler K, Matthaei S, Hamann A, Forst T.

Metabolism. 2006 Jan;55(1):20-5.

PMID:
16324915
16.

Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study.

Pfützner A, Marx N, Lübben G, Langenfeld M, Walcher D, Konrad T, Forst T.

J Am Coll Cardiol. 2005 Jun 21;45(12):1925-31.

18.

Postprandial hypertriglyceridemia and carotid intima-media thickness in north Indian type 2 diabetic subjects.

Ahmad J, Hameed B, Das G, Siddiqui MA, Ahmad I.

Diabetes Res Clin Pract. 2005 Aug;69(2):142-50.

PMID:
15955588
19.

Metabolic syndrome, diabetes and subclinical atherosclerosis as assessed by carotid intima-media thickness.

Kawamoto R, Tomita H, Ohtsuka N, Inoue A, Kamitani A.

J Atheroscler Thromb. 2007 Apr;14(2):78-85.

20.

Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study.

Davidson JA, Perez A, Zhang J; Pioglitazone 343 Study Group.

Diabetes Obes Metab. 2006 Mar;8(2):164-74.

PMID:
16448520

Supplemental Content

Support Center